title: T1-T2 NO oropharyngeal cancers treated with surgery alone. A GETTEC study.
abstract: The aim of this study is to show that surgical treatment of early-stage squamous cell carcinomas of the oropharynx gives identical, if not better, oncological results than the classic radiotherapy treatment in terms of locoregional control and survival. Fifty-three patients (32 T1, 21 T2, all N0) were operated on during the years 1995-2000. Surgical treatment consisted in a resection by the transoral approach in 43 patients (81.13%); ten patients (18.87%) benefited from a pharyngectomy with (seven) or without (three) mandibular resection. A level I to V selective neck dissection was performed on 35 patients, and 5 patients underwent a level II to V selective neck dissection. The 1-, 3- and 5-year overall survival rates were 100, 94.6 and 73%, respectively. There was no significant difference concerning the tumor stage ( P=0.69), the initial localization ( P=0.64), the macroscopic aspect ( P=0.65) and the management undertaken in the different centers ( P=0.19). The 5-year rate of specific survival was 100%. The 1-, 3- and 5-year locoregional control rates were 96.22, 92.45 and 88.68, respectively. The oncological occurrences observed were 2 persistent diseases, 5 local recurrences, 11 second primary cancers and 0 nodal recurrences. Seven local failures were observed, all of which were controlled after a second treatment. Eleven patients presented second primary cancers; three died, two are alive with an extension of this second localization, and six are alive and free of disease. The locoregional control provided by surgery alone on T1-T2 N0 oropharyngeal cancers is as good as radiotherapy. Moreover surgery alone makes it possible to spare patients the complications and aftereffects of radiotherapy. It also makes it possible during the recurrences to operate on patients in non-irradiated areas with lower morbidity and mortality. It is all the more beneficial since it will be possible to resort to radiotherapy after surgery if need be.
authors.affiliation: Service ORL, Hôpital de la Croix-Rousse, 103 grande rue de la Croix-Rousse, 69317 Lyon Cedex 04, France. alain.cosmidis@chu-lyon.fr
authors.forename: Alain
authors.initials: A
authors.lastname: Cosmidis
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Rame
authors.forename: Olivier
authors.initials: O
authors.lastname: Dassonville
authors.forename: Stéphane
authors.initials: S
authors.lastname: Temam
authors.forename: François
authors.initials: F
authors.lastname: Massip
authors.forename: Gilles
authors.initials: G
authors.lastname: Poissonnet
authors.forename: Marc
authors.initials: M
authors.lastname: Poupart
authors.forename: Patrick
authors.initials: P
authors.lastname: Marandas
authors.forename: Dominique
authors.initials: D
authors.lastname: De Raucourt
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D005260:Female; D006801:Humans; D007825:Laryngectomy / Q000379:methods; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology*; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D018570:Risk Assessment; D013515:Surgery, Oral / Q000379:methods; D016019:Survival Analysis; D016896:Treatment Outcome